Presentation is loading. Please wait.

Presentation is loading. Please wait.

Mean LOS and 30-day all-cause readmission rates before and after conversion to the Interdisciplinary Diabetes Care model. Mean LOS and 30-day all-cause.

Published byRosamund Chambers Modified over 5 years ago

Similar presentations

Presentation on theme: "Mean LOS and 30-day all-cause readmission rates before and after conversion to the Interdisciplinary Diabetes Care model. Mean LOS and 30-day all-cause."— Presentation transcript:

1 Mean LOS and 30-day all-cause readmission rates before and after conversion to the Interdisciplinary Diabetes Care model. Mean LOS and 30-day all-cause readmission rates before and after conversion to the Interdisciplinary Diabetes Care model. University HealthSystem Consortium data as of 5 November 2014 are shown. Diabetes as primary diagnosis: pre-intervention n = 706, post-intervention n = 673; diabetes as any diagnosis: pre-intervention n = 9,049, post-intervention n = 9,043. Sandra G. Hardee et al. Diabetes Spectr 2015;28: ©2015 by American Diabetes Association

Download ppt "Mean LOS and 30-day all-cause readmission rates before and after conversion to the Interdisciplinary Diabetes Care model. Mean LOS and 30-day all-cause."

Similar presentations

Diabetes and Gestational Diabetes Trends Among Adults in the U. S

Diabetes and Gestational Diabetes Trends Among Adults in the U. S
with undiagnosed diabetes mellitus by three diagnostic criteria

with undiagnosed diabetes mellitus by three diagnostic criteria
Change (with 95% CI) in outcomes by duration of type 2 diabetes

Change (with 95% CI) in outcomes by duration of type 2 diabetes
(A) Participation rates of primary care paediatricians per region in Bavaria (blue) and the mean number of children screened per primary care paediatrician.

(A) Participation rates of primary care paediatricians per region in Bavaria (blue) and the mean number of children screened per primary care paediatrician.
A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.
Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.

Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.
Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.

Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.
Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Insulin and glucagon secretion: nondiabetic and diabetic subjects.
PWD confidence with key diabetes management activities.

PWD confidence with key diabetes management activities.
PWD who regularly or occasionally engaged in activities to manage their diabetes. PWD who regularly or occasionally engaged in activities to manage their.

PWD who regularly or occasionally engaged in activities to manage their diabetes. PWD who regularly or occasionally engaged in activities to manage their.
Engagement in recommended behaviors to prevent type 2 Diabetes (n=82)

Engagement in recommended behaviors to prevent type 2 Diabetes (n=82)
Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.
Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.
Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.
Flow sheet over the primary study population as well as comparative individuals of “pre-diabetic” individuals followed from HUNT2 to HUNT3 (GAD, glutamic.

Flow sheet over the primary study population as well as comparative individuals of “pre-diabetic” individuals followed from HUNT2 to HUNT3 (GAD, glutamic.
Geographic areas with increased ED visits after Hurricane Sandy by diabetic adults. Geographic areas with increased ED visits after Hurricane Sandy by.

Geographic areas with increased ED visits after Hurricane Sandy by diabetic adults. Geographic areas with increased ED visits after Hurricane Sandy by.
Peter E. Carson et al. JCHF 2015;3:

Peter E. Carson et al. JCHF 2015;3:
Daily changes in ED use compared to baseline utilization in October and November 2012 for patients with diabetes in New York City evacuation zone level.

Daily changes in ED use compared to baseline utilization in October and November 2012 for patients with diabetes in New York City evacuation zone level.
Subgroup analysis of physical activity rates—Asian immigrants versus whites stratified by DM status. Subgroup analysis of physical activity rates—Asian.

Subgroup analysis of physical activity rates—Asian immigrants versus whites stratified by DM status. Subgroup analysis of physical activity rates—Asian.
Yearly trends in percentage of admissions for primary TB cases that occurred in selected high-risk groups from 1992 to 2011: secondary diagnoses of HIV.

Yearly trends in percentage of admissions for primary TB cases that occurred in selected high-risk groups from 1992 to 2011: secondary diagnoses of HIV.

Similar presentations

Ads by Google